Collection
Collection by Dr. Joseph G. Pressey

Desmoid Tumors & Fibromatosis

items total cited expert statements Updated Nov 17, 2026
Start exploring
Try
Intelligent Search· answers come only from this collection · not medical advice
Content of this collection items

At Cincinnati Children's Hospital, gamma secretase inhibitors are considered standard of care for patients requiring medical therapy, especially young adults and older adolescent pediatric patients. — Joseph G. Pressey, "Subtotal Percutaneous Cryoablation for Extra-Abdominal Desmoid Tumors" with Joseph G. Pressey, MD · 1:00

"Subtotal Percutaneous Cryoablation for Extra-Abdominal Desmoid Tumors" with Joseph G. Pressey, MD
"Subtotal Percutaneous Cryoablation for Extra-Abdominal Desmoid Tumors" with Joseph G. Pressey, MD Visit: DTRF.org
video9:32 · Nov 2026
Watch →

Desmoid tumors have a peak incidence in young adulthood and often cause pain, loss of function, and diminished quality of life. Retrospective Case Series Highlighting the Real-World Experience of Nirogacestat Therapy in Young Adults With Desmoid Tumors

Gamma-Secretase Inhibitors2 items
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
Background: Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments. Methods: We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial of nirogacestat in
article · Nov 2026
Read →
Retrospective Case Series Highlighting the Real-World Experience of Nirogacestat Therapy in Young Adults With Desmoid Tumors
Background: With a peak incidence in young adulthood, desmoid tumors (DTs) often cause pain, loss of function, and diminished quality of life. On the basis of findings from the Phase III desmoid fibromatosis (DeFi) trial, the selective gamm
article · Nov 2026
Read →
Tyrosine Kinase Inhibitors1 item
Pazopanib therapy for desmoid tumors in adolescent and young adult patients
Background: Desmoid tumors/aggressive fibromatosis (DT/AF) lack a reliably effective medical therapy. Surgical resection may be morbid and does not preclude recurrence. Radiation may carry severe late effects, particularly detrimental in yo
article · Nov 2026
Read →

A male patient with tuberous sclerosis complex developed chest wall fibromatosis and bilateral multifocal renal cell carcinoma. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex

Single institution series of nodular fasciitis in children
Nodular fasciitis often resembles malignant sarcomas from a clinical and pathologic perspective. We describe the case of an infant that presented with a supraclavicular nodular fasciitis that recurred after an initial gross total resection.
article · Nov 2026
Read →
Solitary myofibroma preceding the development of multicentric myofibromatosis: A report of two cases with surveillance recommendations
Infantile myofibroma is the most common fibrous tumor of infancy. Despite the frequency of these tumors, the natural history is incompletely understood. We present two cases with a unique pattern of disease: solitary myofibromas with subseq
article · Nov 2026
Read →
Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex
A male with tuberous sclerosis complex (TSC) developed a chest wall fibromatosis and bilateral multifocal renal cell carcinoma (RCC). The fibromatosis tumor was initially resected during infancy but recurred 5 years later. At that time, bil
article · Nov 2026
Read →

"Subtotal Percutaneous Cryoablation for Extra-Abdominal Desmoid Tumors" with Joseph G. Pressey, MD
Nirogastat and presumably other gamma secretase inhibitors work well for desmoid tumors based on published DeFi study data.
Host summaryJoseph G. Pressey summarizing a resource — not the host's own clinical position0:46
At Cincinnati Children's Hospital, gamma secretase inhibitors are considered standard of care for patients requiring medical therapy, especially young adults and older adolescent pediatric patients.
Joseph G. Pressey1:00
Cryoablation is an interventional radiology ablative procedure that uses argon gas to create an ice ball.
Joseph G. Pressey2:35
One to three probes are typically used for cryoablation depending on the size and shape of the tumor.
Joseph G. Pressey2:51
The tumor is frozen down to minus 140 to minus 190 degrees Fahrenheit during cryoablation, forming an ice ball around part or all of the tumor.
Joseph G. Pressey3:03
Cincinnati Children's Hospital has been offering cryoablation for desmoid tumors since 2021.
Joseph G. Pressey3:20
Cincinnati Children's uses a standard two-cycle freeze-thaw approach to cryoablation.
Joseph G. Pressey3:31
Nerve monitoring is performed when vital nerves run near the tumor, and skin warming is used to prevent necrosis of overlying skin.
Joseph G. Pressey3:39
Patients are under general anesthesia during cryoablation and typically admitted to the hospital afterwards for pain control, usually overnight but up to three days depending on location and treatment plan.
Joseph G. Pressey3:48
Cryoablation procedures are often ultrasound or CT guided.
Joseph G. Pressey4:03
Cincinnati Children's has treated 14 patients with 25 technically successful cryoablation procedures for desmoid tumors.
Joseph G. Pressey4:06
The patient cohort ranged from 8 to 43 years of age with a median age of 20 years.
Joseph G. Pressey4:15
Patients required one to three probes during therapy and had anywhere from one to four procedures depending on tumor size and shape.
Joseph G. Pressey4:22
Some tumors got larger after cryoablation while others dramatically shrunk in size.
Joseph G. Pressey4:30
Tumors that decreased in size also showed decreased T2 hyperintensity on MRI.
Joseph G. Pressey4:43
At 12 months after cryoablation, 86% of patients had not started a new medical therapy.
Joseph G. Pressey5:36
At 36 months after cryoablation, 55% of patients had not started a new medical therapy.
Joseph G. Pressey5:36
The patient cohort was heterogeneous and many had been heavily pre-treated.
Joseph G. Pressey5:42
Pazopanib is very much like sorafenib, cousins in effect.
Joseph G. Pressey6:10
Nine out of 13 patients reported improved pain after cryoablation.
Joseph G. Pressey7:34
Six out of 11 patients reported improved function after cryoablation.
Joseph G. Pressey7:34
There were no grade 3 or grade 4 toxicities from cryoablation in this cohort.
Joseph G. Pressey7:41
Cincinnati Children's has taken a modest approach where 30 to 90% of the tumor is frozen, not attempting to freeze the entire tumor unless very easy to do.
Joseph G. Pressey7:44
Subtotal cryoablation was found to be effective and safe.
Joseph G. Pressey8:11
Approximately half of the patients did not require subsequent new medical therapy after undergoing cryoablation.
Joseph G. Pressey8:18
Many patients had received medical therapy up until the point where they underwent cryoablation.
Joseph G. Pressey8:26
There appear to be no overlapping toxicities between prior medical therapy and subsequent cryoablation.
Joseph G. Pressey8:33
Retrospective Case Series Highlighting the Real-World Experience of Nirogacestat Therapy in Young Adults With Desmoid Tumors
Desmoid tumors have a peak incidence in young adulthood and often cause pain, loss of function, and diminished quality of life.
Established practice
Nirogacestat, a selective gamma secretase inhibitor, was approved by the US Food and Drug Administration in November 2023 for the treatment of patients with desmoid tumors based on findings from the Phase III DeFi trial.
Established practice
The median patient age in this series was 26 years.
Cites published research
GCMD Library — Curated collection · summaries prepared automatically from the recordings · educational content, not medical advice
Start the course
We remember your choice for this collection.
Follow this collection We'll email you when something new is added to Desmoid Tumors & Fibromatosis — the new recordings themselves, with links. Nothing when nothing is added; every email has an unsubscribe link.